1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Sir Jonathan Symonds
| |||
b)
|
Position/status
|
Non-Executive Chairman
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.94
|
3,138.451
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr Charles Bancroft
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$39.09
|
1,479.486
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr Vindi Banga
| |||
b)
|
Position/status
|
Senior Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.94
|
650.108
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr Anne Beal
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$39.09
|
200.787
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr Vivienne Cox
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.94
|
605.273
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms Lynn Elsenhans
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$39.09
|
285.330
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr Laurie Glimcher
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$39.09
|
1,056.776
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr Jesse Goodman
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$39.09
|
348.736
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Mr Urs Rohner
| |||
b)
|
Position/status
|
Independent Non-Executive Director
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2021 to 30 September 2021
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
£13.94
|
605.273
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume
Price
| |||||
e)
|
Date of the transaction
|
2021-09-20
| |||
f)
|
Place of the transaction
|
N/A
|
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 22 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2021 16:11:04 UTC.